AR124749A1 - Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades - Google Patents

Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades

Info

Publication number
AR124749A1
AR124749A1 ARP200100485A ARP200100485A AR124749A1 AR 124749 A1 AR124749 A1 AR 124749A1 AR P200100485 A ARP200100485 A AR P200100485A AR P200100485 A ARP200100485 A AR P200100485A AR 124749 A1 AR124749 A1 AR 124749A1
Authority
AR
Argentina
Prior art keywords
independently selected
optionally substituted
alkyl optionally
alkyl
membered monocyclic
Prior art date
Application number
ARP200100485A
Other languages
English (en)
Spanish (es)
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of AR124749A1 publication Critical patent/AR124749A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ARP200100485A 2019-02-25 2020-02-21 Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades AR124749A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1902490.0A GB201902490D0 (en) 2019-02-25 2019-02-25 Novel compounds and pharmaceutical compositions thereof for the treatment of diseases

Publications (1)

Publication Number Publication Date
AR124749A1 true AR124749A1 (es) 2023-05-03

Family

ID=65998935

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200100485A AR124749A1 (es) 2019-02-25 2020-02-21 Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de enfermedades

Country Status (19)

Country Link
US (1) US20220144823A1 (cg-RX-API-DMAC10.html)
EP (1) EP3931191B1 (cg-RX-API-DMAC10.html)
JP (1) JP2022525121A (cg-RX-API-DMAC10.html)
KR (1) KR20210134001A (cg-RX-API-DMAC10.html)
CN (1) CN113474344A (cg-RX-API-DMAC10.html)
AR (1) AR124749A1 (cg-RX-API-DMAC10.html)
AU (1) AU2020229041A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021016642A2 (cg-RX-API-DMAC10.html)
CA (1) CA3130154A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021010485A2 (cg-RX-API-DMAC10.html)
ES (1) ES2963409T3 (cg-RX-API-DMAC10.html)
GB (1) GB201902490D0 (cg-RX-API-DMAC10.html)
IL (1) IL285751A (cg-RX-API-DMAC10.html)
MA (1) MA55074A (cg-RX-API-DMAC10.html)
MX (1) MX2021010093A (cg-RX-API-DMAC10.html)
PH (1) PH12021552032A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202109157TA (cg-RX-API-DMAC10.html)
TW (1) TW202045505A (cg-RX-API-DMAC10.html)
WO (1) WO2020173739A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022070288A1 (ja) * 2020-09-30 2022-04-07 旭化成ファーマ株式会社 含窒素二環化合物
WO2025143152A1 (ja) * 2023-12-27 2025-07-03 全薬工業株式会社 チアゾリル-ピラゾロ[1,5-a]ピリジン化合物、およびそのMYLK4阻害剤としての使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2048142A3 (en) * 2001-04-26 2009-04-22 Eisai R&D Management Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
CA2732520A1 (en) * 2008-08-05 2010-02-11 Merck Sharp & Dohme Corp. Therapeutic compounds
JP2012516329A (ja) * 2009-01-30 2012-07-19 ミレニアム ファーマシューティカルズ, インコーポレイテッド Pi3k阻害剤としてのヘテロアリールおよびその使用
WO2014066795A1 (en) * 2012-10-25 2014-05-01 Bioenergenix Heterocyclic compounds for the inhibition of pask
EP3227286B1 (de) * 2014-12-02 2018-12-26 Bayer Pharma Aktiengesellschaft Substituierte pyrazolo[1,5-a]pyridine und imidazo[1,2-a]pyrazine und ihre verwendung
JP7175917B2 (ja) * 2017-04-27 2022-11-21 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 新規のalk2阻害剤及びbmpシグナル伝達の阻害方法

Also Published As

Publication number Publication date
CN113474344A (zh) 2021-10-01
PH12021552032A1 (en) 2022-11-14
WO2020173739A1 (en) 2020-09-03
IL285751A (en) 2021-10-31
SG11202109157TA (en) 2021-09-29
MA55074A (fr) 2022-01-05
JP2022525121A (ja) 2022-05-11
KR20210134001A (ko) 2021-11-08
GB201902490D0 (en) 2019-04-10
EP3931191A1 (en) 2022-01-05
EP3931191B1 (en) 2023-10-04
ES2963409T3 (es) 2024-03-27
TW202045505A (zh) 2020-12-16
AU2020229041A1 (en) 2021-10-21
CA3130154A1 (en) 2020-09-03
BR112021016642A2 (pt) 2021-11-03
MX2021010093A (es) 2021-09-21
CO2021010485A2 (es) 2021-08-19
US20220144823A1 (en) 2022-05-12

Similar Documents

Publication Publication Date Title
AR104362A1 (es) Dihidropiridoisoquinolinonas y composiciones farmacéuticas de las mismas para el tratamiento de trastornos inflamatorios
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR113909A1 (es) Compuestos y sus composiciones farmacéuticas para el tratamiento de hepatitis b
AR097862A1 (es) Inhibidores de tirosina quinasa de bruton
MX2019000123A (es) Derivados de 1,3-dihidroxi-fenilo utiles como inmunomoduladores.
AR091858A1 (es) INHIBIDORES DE CISTATIONIN-g-LIASA (CSE)
AR106865A1 (es) Piridinas sustituidas y métodos de uso
AR104880A1 (es) MODULADORES DE ROR GAMMA (RORg)
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR116283A1 (es) Inhibidores del sarcómero cardíaco
AR088175A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen
AR094668A1 (es) Amidas como moduladores de canales de sodio
CL2022001741A1 (es) Compuestos cíclicos y métodos de uso de estos
AR107032A1 (es) Inhibidores bicíclicos de pad4
AR094537A1 (es) COMPUESTOS DE PIRIDILO SUSTITUIDOS CON ALQUILAMIDA ÚTILES COMO MODULADORES DE LAS RESPUESTAS DE IL-12, IL-23 Y/O IFNa
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
PE20181778A1 (es) Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue
AR108906A1 (es) Heterociclos de biarilmetilo
AR100809A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR116114A1 (es) Amidas heterocíclicas de entre 5 y 7 miembros como inhibidores de jak
AR116115A1 (es) Dimetil amino azetidina amidas como inhibidores de jak
AR098522A1 (es) Compuesto de triazolo-piridina
AR118521A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de trastornos inflamatorios
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR104878A1 (es) MODULADORES DE ROR GAMMA (RORg)

Legal Events

Date Code Title Description
FA Abandonment or withdrawal